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the plot of raw output versus pulses at least one day prior to the 
failure. 
Conclusions: Energy variations of Tomo HD can be monitored by Exit 
Detector Flatness in the TQA software. Abnormal waveforms from raw 
output can be observed before a magnetron failure in more than half 
of the cases. 
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Purpose/Objective: 3D dose and dose volume histogram (dvh) 
calculation is a new option of the delta 4 phantom for pre-treatment 
verification; dose deviation can be rated differently depending on 
where it occurs: in a target, in an organ at risk or in a non critical 
structure. For example an under dosage in an organ at risk should not 
trigger a fail-indication whereas a similar under dosage in a target 
definitely should trigger a fail indication. The purpose of this study is 
to evaluate the Dose volume histrograms of 250 patients measured 
with Delta 4 diode array Phantom (Scandidos), grouped per pathology 
and tumor site and to find some new acceptance criteria based on 
clinical significance. 
Materials and Methods: 250 patients were treated using VMAT arc 
delivery for various tumor sites; all treatments were planned with 
Elekta Monaco planning system (ver. 3.2) and delivered on an Elekta 
Synergy (40x40 cm2field size without interdigitation) or on an Elekta 
Axesse (21x16 cm2field size with 0.4 cm leaves with full 
interdigitation). Each treatment plan was then measured using Delta 4 
diode array cylindrical phantom. First all measurements were 
compared to the treatment planning system dose distribution via 
gamma analysis (3 % dose difference , 3 mm distance to agreement 
criteria) .The presence of the carbon fiber couch was taken into 
account. The software of the Delta 4 defines ROI inside the phantom 
that are identical to the imported patient structures regarding shape 
and position towards the isocenter, therefore dvhs where calculated 
inside the cylindrical homogenous phantom for planned and measured 
3D dose distribution. The patients were divided into nine groups 
according to tumor site (anus , head&neck, snc, liver, lung, lung 
sbrt,rectum, prostate, mediastinum) and, for each site, the most 
critical organs at risk were selected. We compared dvhs parameters 
such as V95% and V107% for PTV, D1 for spinal cord , median dose for 
parotids and so on for the dose calculated and measured. 
Results: In the table is shown the result of the gamma analysis for all 
patients.If Γ(3mm, 3%) = 90% is a reasonable cutoff for accepting the 
plan , we found 14% of the patients having a gamma value less then 
acceptance criteria. Performing the dvhs analysis for these patients, 
comparing calculated and measured parameters, we found a 
discrepancy between values of the most critical organ at risk more 
than 5% only in 4% of the all patients; for these patients, we have 
definitively rejected the plan. 
 
 
 
 
 
Conclusions: One of the main benefits in making pre-treatment 
verification based on 3D and dvhs data is that acceptance criteria 
might be based on clinica lsignificance: you can evaluate if the 
discrepancy between measured and planned dose is in a critical organ 
or if it is in the healthy tissue. We propose aselection criteria based 
on the evaluation of the gamma index of the dosedistribtion and the % 
difference of the constraints between calculated and measured plan. 
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Purpose/Objective: The investigation was performed in order to 
compare radiotherapy dose distributions in tissues surrounding the 
titanium or resorbable implants used clinically for joining and 
consolidating of the facial bones. Inhomogeneous dose distributions 
can be a reason of the normal tissue complications observed during 
the radiotherapy of patients after surgery during which the titanium 
plates were implanted. The knowledge about the distribution of the 
dose around the implants would help to decide whether to preserve or 
to remove the implants before irradiation. 
Materials and Methods: The commonly available resorbable implants 
require comparing them with the titanium implants in case of patients 
requiring radiotherapy after surgery. The dose distributions around 
the titanium and around the resorbable implants were measured and 
compared. Nucletron Oncentra MasterPlan treatment planning system 
(TPS) was used for the calculation of the dose distributions. For 
measurements, Gafchromic EBT radiochromic dosimetry films were 
used for recording the dose distributions in tissue equivalent 
phantoms. The phantoms and films were irradiated with 4 MV photon 
beams of Varian Clinac 600C/D linear accelerator.The irradiated films 
were digitized with Epson 10000XL flat bed scanner and the dose 
distributions were compared using 3Cognition FilmQA software. 
Results: The dose measured on the contact surfaces between the 
titanium implant and the phantom material proximal and distal to the 
beam source at depth of 2.5 cm were 109% and 92% of the reference 
dose measured in homogenous tissues without the implants, 
respectively. For the resorbable implants the doses measured on the 
proximal and the distal contact surfaces were 102% and 101% of the 
reference dose respectively. An interaction of ionization radiation 
with the titanium reconstruction plates is widely discussed in the 
literature. The distortions of the homogenous dose distribution around 
the implants appear only at the distance of few millimeters, but this 
is often more than the thickness of the normal tissue or even the 
tumor in that localization. Clinically, the risk of complications should 
be regarded in form of early or late complications or recurrent 
tumors. 
Conclusions: The titanium plates significantly affect the homogeneity 
of the dose distribution and create the underdose and overdose 
regions. Apart of these effects the presence of the titanium implants 
during the computer tomography examination creates the image 
artifacts which may significantly disturb the target volume delineation 
as well as the early detection of the recurrent cancer in the cavities 
after surgery. The resorbable implants affect the homogeneity of dose 
distributions in significantly lesser degree in the irradiated media and 
their presence does not generate the image artifacts during CT 
examinations.  
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Purpose/Objective: At the moment it is recommended to perform an 
independent check of the MUs calculated by the treatment planning 
system (TPS). In modern complex treatment techniques it is not 
feasible to perform these checks by hand, Diamond (PTW Freiburg) is 
a secondary check software that allows independent MU and point 
dose verification for conformal and IMRT treatment plans which 
validation has been already reported in the literature. The purpose of 
this work is to describe the practical aspects and results in our 
experience in using Diamond for RapidArc (RA) treatments. 
Materials and Methods: Our department has been recently equipped 
with 3 Varian linacs (with RA) and 6 Eclipse (10.0) TPS stations that 
are used to calculate dose distributions. As a part of our QC program 
all the dose calculations are independently checked, in particular our 
IMRT pre-treatment protocol establishes that prior to each treatment, 
calculations are verified at least with Diamond software (PTW), Portal 
Dosimetry (Varian) and Octavius4D (PTW). For the MU/point dose 
verification Dicom files exported from Eclipse (dose, plan and 
structure) are imported by Diamond which compares results against 
the TPS. The isocenter coordinates and dose are automatically read by 
Diamond to perform the comparison, but if it is not a representative 
dose point for all the arcs, extra points must be generated in Eclipse 
and manually introduced in Diamond. We have analyzed the results of 
the comparisons as well the practical questions that have arisen. 
Results: More than 700 plans have been calculated since February 
2012, being about 45% RA treatments. Several arcs are commonly used 
(1-4), 2 for the majority of the plans (65%). The average obtained 
deviation has been 0.29%, being the maximum found deviation of 8% 
in a point. The verification takes about 15 minutes to be performed 
including the time needed to introduce the extra dose points that are 
not read by Diamond. The main practical drawbacks that we have 
faced are: the program automatically reads the structures file in order 
to take into account the patient contour and consequently the depth 
at each control point of the arc, but when the external contour 
 DTA Γ 3% 3mm Γ 5% 3mm
mean 96.6 93.8 97.14 
Dev st 7 7 4.7 
